Novartis' substantial $12 billion investment into Avidity Biosciences is demonstrating its value, as early outcomes from the Phase 1/2 FORTITUDE trial for del-brax, targeting facioscapulohumeral muscular dystrophy (FSHD), have successfully achieved both its main and secondary objectives. This promising development indicates a significant stride in the treatment of uncommon neuromuscular conditions, highlighting the transformative potential of advanced therapeutic approaches to enhance patient well-being.

Facioscapulohumeral muscular dystrophy (FSHD) is a debilitating genetic disorder characterized by progressive weakening of skeletal muscles, leading to pain, persistent fatigue, and significant physical impairment. It is estimated to affect between 45,000 and 87,000 individuals across the United States and Europe, imposing a considerable burden on patients and healthcare systems alike. The condition's progressive nature means that symptoms often worsen over time, severely impacting quality of life and daily activities for those affected.

Novartis announced encouraging findings from the biomarker segment of its Phase 1/2 FORTITUDE investigation. The study demonstrated successful fulfillment of its main and key secondary objectives concerning del-brax, an experimental treatment for FSHD. The company highlighted significant reductions in KHDC1L (cDUX), a biomarker associated with DUX4 gene expression, alongside decreased levels of creatine kinase, an indicator of muscle damage. These results signify strong therapeutic engagement and a notable reduction in muscle injury among participants, validating the drug's mechanism of action.

Del-brax, an innovative antibody oligonucleotide conjugate (AOC), is specifically engineered to target the fundamental cause of FSHD by inhibiting the abnormal expression of the DUX4 gene. This therapeutic approach merges the precision of monoclonal antibodies with oligonucleotide technology to deliver small interfering RNA directly into muscle cells. Novartis asserts that del-brax is currently the sole investigational therapy to exhibit disease-modifying capabilities for FSHD in clinical research. The treatment has been granted Orphan Drug and Fast Track designations by the FDA, as well as an Orphan Drug designation from the European Medicines Agency, and is presently undergoing Phase 3 evaluation.

The successful trial outcomes build on prior observations from early dose-escalation cohorts, which also indicated favorable target engagement and muscle protection. This consistency in results underscores the therapy's potential efficacy and supports the dosage regimen now being utilized in the ongoing Phase 3 trial. Novartis is meticulously evaluating the comprehensive biomarker and clinical data and plans to engage with regulatory bodies globally to discuss the continued development and potential approval of del-brax.

The acquisition of Avidity Biosciences by Novartis in February 2026 for $12 billion brought del-brax into Novartis' neuroscience portfolio. This strategic move also included other promising therapies such as delpacibart-etedesiran (del-desiran), which is in Phase 3 development for myotonic dystrophy type 1, and delpacibart-zotadirsen (del-zota), currently in Phase 2 for Duchenne muscular dystrophy. The ongoing Phase 3 FORTITUDE-3 trial is actively recruiting 200 FSHD patients, aged 16 to 70 years, to further assess the efficacy and safety of del-brax using various clinical and patient-reported outcome measures.

The latest positive findings from the del-brax study reinforce Novartis' dedication to pioneering treatments for rare diseases, particularly within its expanding neuromuscular pipeline. This therapeutic candidate offers a beacon of hope for patients affected by FSHD, who currently have limited treatment options. The company's proactive engagement with global regulatory authorities signifies a commitment to advancing this therapy through its final developmental stages, potentially bringing a much-needed disease-modifying treatment to market.